“Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 2 Trial”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 6, Nov. 2025, p. s692, https://doi.org/10.25251/w6str133.